ReviewThe journal of allergy and clinical immunology. In practice
SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.
Review in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Systemic Therapy for Paediatric Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Current Evidence and Limitations.Journal of paediatrics and child health · 2026Pooled it
- Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.The Cochrane database of systematic reviews · 2022Pooled it
- Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020.Frontiers in medicine · 2022Pooled it
- Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis.The pharmacogenomics journal · 2019Pooled it
- Summary of Best Evidence for Wound Management in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Acta dermato-venereologica · 2026Review
- The Use of Systemic Immunomodulating Drugs and Management Practices in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis among Dermatologists in the Philippines: A Cross-sectional Survey Study.Acta dermato-venereologica · 2026Article
- Machine learning-based model for prediction of carbamazepine- and allopurinol-induced severe cutaneous adverse reactions in Vietnamese.The World Allergy Organization journal · 2026Article
- Toxic Epidermal Necrolysis in a Patient with Hepatocellular Carcinoma Receiving Pembrolizumab Plus Regorafenib: A Case Report.Cancer management and research · 2026Article
- Prospective longitudinal study of psychological sequelae, self-perception of body image, and quality of life in severe cutaneous adverse drug reactions: a case-control study.Frontiers in medicine · 2026Article
- Comparative Impact of NSAIDs Versus Acetaminophen on Mortality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Cohort Study of 2484 Patients From a Nationwide Inpatient Database.The Journal of dermatology · 2026Article
- Attribution of causality in Stevens-Johnson syndrome/toxic epidermal necrolysis.The ocular surface · 2025Review
- Challenges in Diagnosing and Treatment of Pediatric Necrotic Skin Conditions: A Retrospective Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis.Investigational new drugs · 2025Article
- Emerging causes of anticancer therapies-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system.Frontiers in immunology · 2025Article
- Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management.American journal of clinical dermatology · 2024Review
- The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) - Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions.The World Allergy Organization journal · 2024Article
- Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis.Toxicological sciences : an official journal of the Society of Toxicology · 2024Review
- Toxic epidermal necrolysis complicated with respiratory failure in children: A case report.Heliyon · 2024Article
- Tumor necrosis factor-α inhibitor for successful treatment of toxic epidermal necrolysis with severe infection: a case series.The Journal of international medical research · 2024Article
- Editorial: Stevens Johnson syndrome: past, present, and future directions.Frontiers in medicine · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
44 authors.
Funding
Abstract
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to 5 per 1,000,000. To effect significant reduction in short- and long-term morbidity and mortality, and advance clinical care and research, coordination of multiple medical, surgical, behavioral, and basic scientific disciplines is required. On March 2, 2017, an investigator-driven meeting was held immediately before the American Academy of Dermatology Annual meeting for the central purpose of assembling, for the first time in the United States, clinicians and scientists from multiple disciplines involved in SJS/TEN clinical care and basic science research. As a product of this meeting, this article summarizes the current state of knowledge and expert opinion related to SJS/TEN covering a broad spectrum of topics including epidemiology and pharmacogenomic networks; clinical management and complications; special populations such as pediatrics, the elderly, and pregnant women; regulatory issues and the electronic health record; new agents that cause SJS/TEN; pharmacogenomics and immunopathogenesis; and the patient perspective. Goals include the maintenance of a durable and productive multidisciplinary network that will significantly further scientific progress and translation into prevention, early diagnosis, and management of SJS/TEN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.